hexadecyl L-alaninate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: hexadecyl L-alaninate
• 英文别名: L-alanine cetyl ester；hexadecyl (2S)-2-aminopropanoate
• 化学式: C₁₉H₃₉NO₂
• 分子量: 313.524
• InChiKey: UCCMBYBOOAOUMZ-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  22
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  hexadecyl L-alaninate 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 54.0h， 生成
  参考文献：
  名称：

  Irregular cationic lipotetrapeptides for pharmaceutical multifunctional transport systems

  摘要：

  DOI：

  10.1016/j.mencom.2021.07.024
• 作为产物：
  描述：

  L-丙氨酸 生成 hexadecyl L-alaninate
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Superior SWNT dispersion by amino acid based amphiphiles: designing biocompatible cationic nanohybrids
  作者：Sayanti Brahmachari、Dibyendu Das、Prasanta Kumar Das

  DOI：10.1039/c0cc02464c

  日期：——

  Stable aqueous SWNT dispersion up to 92% was achieved using amino acid based amphiphiles through a structure–property investigation. The nanohybrids showed remarkable serum stability and biocompatibility to mammalian cells.

  通过结构–性能研究，利用氨基酸基表面活性剂实现了高达92%稳定性的水溶性SWNT分散。这些纳米复合物表现出卓越的血液稳定性及对哺乳动物细胞的生物相容性。
• [EN] COMPOUNDS USEFUL IN HIV THERAPY<br/>[FR] COMPOSÉS UTILES DANS LA THÉRAPIE DU VIH
  申请人：VIIV HEALTHCARE CO

  公开号：WO2021194828A1

  公开（公告）日：2021-09-30

  The invention relates to compounds of Formula (I), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.

  这项发明涉及公式（I）的化合物，其盐，药物组合物，以及治疗或预防HIV的方法。
• Differential scanning calorimetric and powder X-ray diffraction studies on a homologous series of N-acyl-L-alanine esters with matched chains (n = 9-18)
  作者：D SIVARAMAKRISHNA、MUSTI J SWAMY

  DOI：10.1007/s12039-015-0928-5

  日期：2015.9

  alternation with compounds bearing odd acyl and alkyl chains showing higher values of T t, ΔH t and ΔS t as compared to NAAEs with even acyl and alkyl chains. However, the transition enthalpies and entropies of the odd- and even chain length series independently exhibit a linear dependence on the chain length. The d-spacings obtained from PXRD increase linearly with chain length with an increment of 1.76 Å/CH

  已经合成了L-丙氨酸的两个链衍生物的同系物，即带有匹配的，饱和的，酰基和烷基链（n＝ 9-18）的N-酰基L-丙氨酸烷基酯（NAAE）。通过差示扫描量热法（DSC）和粉末X射线衍射（PXRD）研究了NAAE的热致相变和超分子结构。DSC研究的结果表明，转变温度（T t），焓（ΔH t）和熵（ΔS t）与带有奇数酰基和烷基链的化合物表现出奇偶交替，表现出更高的T t，ΔH值t和Δ 与具有偶数酰基和烷基链的NAAE相比，S t更大。但是，奇数和偶数链长序列的跃迁焓和熵独立地表现出对链长的线性依赖性。从PXRD获得的d间距随链长线性增长，增幅为1.76Å / CH 2，表明NAAE采用倾斜的双层结构或弯曲的结构。本研究结果为研究NAAE与其他膜脂的相互作用提供了热力学和结构基础，从而反过来可以帮助我们了解它们如何增强角质层的透皮渗透性。 DSC对带有匹配，饱和，酰基和烷基链（n = 9-18）的
• Contrast agents
  申请人：——

  公开号：US20040146462A1

  公开（公告）日：2004-07-29

  Ultrasonic visualisation of a subject, particularly of perfusion in the myocardium and other tissues, is performed using novel gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase in vivo following administration and can therefore act as deposited perfusion tracers. The preparations comprise an injectable aqueous medium comprising dispersed gas and an injectable oil-in-water emulsion in which the oil phase comprises a diffusible component capable of diffusion in vivo into the dispersed gas to promote temporary growth thereof, such that material present at the surfaces of the dispersed gas phase and material present at the surfaces of the dispersed oil phase have affinity for each other, e.g. as a result of having opposite charges. In cardiac perfusion imaging the preparations may advantageously be coadministered with vasodilator drugs such as adenosine in order to enhance the differences between return signal intensity from normal and hypoperfused myocardial tissue respectively.

  使用新型含气对比剂制剂进行超声成像，特别是心肌和其他组织的灌注成像，这些制剂促进体内气相的可控、暂时性生长，因此可以作为沉积的灌注示踪剂。这些制剂包括可注射的水性介质，其中包含分散的气体和可注射的油水乳液，其中油相包含可扩散的成分，能够在体内扩散到分散的气体中促进其暂时性生长，使分散气体相和分散油相表面的物质互相吸引，例如由于具有相反的电荷。在心脏灌注成像中，这些制剂可以优势地与血管扩张药物（如腺苷）同时使用，以增强正常和低灌注心肌组织的回波信号强度差异。
• Proteinaceous emulsifier, process for preparing same and emulsion type
  申请人：Kanebo Ltd.

  公开号：US04826818A1

  公开（公告）日：1989-05-02

  A proteinaceous emulsifier can be obtained by reacting an amino acid ester with a hydrophilic protein in the presence of an endopeptidase to form decomposition products of the hydrophilic protein having a carboxyl end group joined to the amino group of the amino acid ester by amide linkage. This proteinaceous emulsifier has a typical surfactant structure in which a hydrophobic portion consisting of the amino acid ester is attached to the rear end of a hydrophilic portion consisting of the protein, and is characterized by causing little irritation to the skin, exhibiting strong emulsifying power and possessing moisture retention properties. Thus, it is very suitable for use as an emulsifier in various cosmetics such as creams, milky lotions and the like.

  一种蛋白质乳化剂可以通过在内肽酶存在下，将氨基酸酯与亲水性蛋白质反应，形成水解产物，其羧基末端通过酰胺键连接到氨基酸酯的氨基末端。这种蛋白质乳化剂具有典型的表面活性剂结构，其中由氨基酸酯组成的疏水部分附着在由蛋白质组成的亲水部分的后端，其特点是对皮肤刺激小，具有强大的乳化能力和保湿性能。因此，它非常适合用作各种化妆品，如面霜、乳液等中的乳化剂。